Predictors of return to work ten months after primary breast cancer surgery

Predictors of return to work ten months after primary breast cancer surgery
复制标题

DOI:
10.1080/02841860802477899
复制
发表时间:
2009-01-01
期刊:
影响因子:
3.1
通讯作者:
Olsson, Mariann
Olsson, Mariann
中科院分区:
医学3区
文献类型:
--
作者:
Johnsson, Aina;Fornander, Tommy;Olsson, Mariann

文献摘要

被引文献

相似文献

背景在西方国家,最常见的女性癌症是乳腺癌,被诊断患有这种疾病的女性通常在65岁以下。随着幸存者人数的增加,重要的是要揭示这些妇女在诊断和治疗后面临的问题。本研究的目的是评估预测早期乳腺癌妇女重返工作(RTW)的因素。材料和方法。一组102名年龄在18-64岁之间的早期乳腺癌患者接受了根治性初次手术,有或没有全身辅助治疗,使用问卷调查和医疗档案中的数据进行了10个月的随访。结果初次手术后10个月,59%的女性重返工作岗位,41%的女性兼职或全职生病。在调整了年龄,健康状况,生活满意度,职业状况和乳房/胸壁和区域淋巴结的照射后,多变量logistic回归显示以下因素与RTW呈负相关:高要求工作(OR = 0.1,95%CI 0.0-0.8)、腋窝淋巴结清扫(OR = 0.1,95%CI 0.0-0.6)和化疗(OR = 0.1,95%CI 0.0-0.7)。讨论治疗因素和工作中的高要求在早期乳腺癌女性的RTW中起着重要作用。
Background. The most common female cancer in Western countries is breast cancer and women diagnosed with this disease are often under 65 years old. With increasing prevalence of survivors it is important to shed light on problems facing these women after diagnosis and treatment. The aim of this study was to assess factors predicting return to work (RTW) in women with early-stage breast cancer. Material and methods. A cohort of 102 women aged 18-64 with early-stage breast cancer who had undergone curative primary surgery with or without systemic adjuvant therapy were followed for 10 months using data from questionnaires and medical files. Results. Ten months after primary surgery, 59% of the women had returned to work while 41% were sick-listed part-time or full-time. After adjusting for age, health status, life satisfaction, vocational situation, and irradiation to the breast/chest wall and regional nodes, a multivariate logistic regression revealed the following factors as being negatively associated with RTW: a high-demand job (OR = 0.1, 95% CI 0.0-0.8), axillary node dissection (OR = 0.1, 95% CI 0.0-0.6), and treatment with chemotherapy (OR = 0.1, 95% CI 0.0-0.7). Discussion. Treatment factors and high demands at work play an important role in RTW for women with early-stage breast cancer.